SCHEMBL6325568

SCHEMBL6325568

CN(C)CCS(=O)(=O)N(C)c1ccc(N)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 2/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
PHLPP2 Q6ZVD8 1/20 0.39
TSHR P16473 3/20 0.38
RECQL P46063 2/20 0.38
PSMD14 O00487 1/20 0.38
GFER P55789 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.36
HTR6 P50406 2/20 0.35
MAPT P10636 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.34
LMNA P02545 1/20 0.33
MPO P05164 1/20 0.33
CYP2C9 P11712 1/20 0.33
LOX P28300 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9258237 0.82 F2 (0.42) TDP1ALDH1A1TP53TSHRRECQL
SCHEMBL9790473 0.77 ALDH1A1 (0.37) CYP3A4TDP1ALDH1A1MAPK1TP53
SCHEMBL6328229 0.77 MAPT (0.49) CYP3A4TDP1ALDH1A1MAPK1PHLPP2
SCHEMBL3571750 0.74 GAA (0.57) CYP3A4TDP1ALDH1A1PHLPP2TSHR
SCHEMBL3157904 0.74 ALDH1A1 (0.41) CYP3A4TDP1ALDH1A1MAPK1TP53
SCHEMBL4692769 0.74 CYP3A4 (0.48) CYP3A4TDP1ALDH1A1MAPK1TP53
SCHEMBL4494114 0.73 ALDH1A1 (0.38) CYP3A4TDP1ALDH1A1MAPK1TP53
Hydrochloric Acid SCHEMBL9268959 0.73 F2 (0.41) TDP1TP53TSHRRECQLHTR6
SCHEMBL1916178 0.72 ALDH1A1 (0.52) CYP3A4TDP1ALDH1A1MAPK1TP53
SCHEMBL20389415 0.72 HSP90AA1 (0.49) CYP3A4TDP1ALDH1A1MAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed
EP-1115704-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES Boehringer Ingelheim Pharma KG (DE) 2001-07-18 EP disclosed
WO-2000018734-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 CYP3A4 1136/4885TDP1 1212/4885ALDH1A1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.